X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Telix Pharmaceuticals have access to lead investigational drug Cycloslam (samarium-153-DOTMP) for the treatment of therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
Lead Product(s): Samarium-153-DOTMP
Therapeutic Area: Oncology Product Name: CycloSam
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Telix Pharmaceuticals
Deal Size: $123.1 million Upfront Cash: $33.1 million
Deal Type: Acquisition February 07, 2024
Details:
Through the acquisition, Telix gain rights to CycloSam (samarium-153-DOTMP), a novel, de-risked clinical asset that has the potential to deliver tangible improvements of prior bone-seeking agents.
Lead Product(s): Samarium-153-DOTMP
Therapeutic Area: Oncology Product Name: CycloSam
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Telix Pharmaceuticals
Deal Size: $125.1 million Upfront Cash: $2.0 million
Deal Type: Acquisition November 13, 2023
Details:
Patent covers both formulation and preparation of Samarium-153-DOTMP (CycloSam®), in U.S. with DOTMP kit formulations for radioisotope delivery targeting bone tumors, as well high-dosage use of radiopharmaceutical to perform bone marrow ablations.
Lead Product(s): Samarium-153 DOTMP
Therapeutic Area: Oncology Product Name: CycloSam
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
